Targeting ERBB receptors to inhibit metastasis: Old hopes and new certainties

Current Cancer Drug Targets

Volumn 9, Issue 1, 2009, Pages 1-18

  Angelucci, Adriano ^a  

^a UNIVERSITY OF L'AQUILA   (Italy)

Author keywords

Clinical trials; EGF; Epidermal growth factor; Targeted therapy; Tumor invasion; Tyrosine kinases

Indexed keywords

ANTHRACYCLINE DERIVATIVE; AROMATASE INHIBITOR; CAPECITABINE; CARBOPLATIN; CETUXIMAB; CISPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR 3; EPIDERMAL GROWTH FACTOR RECEPTOR 4; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; FLUOROURACIL; FOLINIC ACID; GEFITINIB; GEMCITABINE; IRINOTECAN; LAPATINIB; MOLECULAR MARKER; MONOCLONAL ANTIBODY; NAVELBINE; OXALIPLATIN; PACLITAXEL; PANITUMUMAB; PLATINUM DERIVATIVE; TRASTUZUMAB; UNINDEXED DRUG;

ADD ON THERAPY; ADVANCED CANCER; ANTINEOPLASTIC ACTIVITY; BINDING SITE; BRAIN METASTASIS; BREAST CANCER; CANCER CELL; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER INVASION; CANCER PATIENT; CANCER STAGING; CANCER SURVIVAL; CANCER THERAPY; CARDIOTOXICITY; CELL FUNCTION; CLINICAL TRIAL; COLON CANCER; COLORECTAL CANCER; DIMERIZATION; DISEASE ASSOCIATION; DOWNSTREAM PROCESSING; DRUG TARGETING; ENZYME ACTIVATION; ENZYME ACTIVITY; FOOD AND DRUG ADMINISTRATION; GENE OVEREXPRESSION; GENE TARGETING; GENETIC EPIGENESIS; HOST CELL; HUMAN; LUNG NON SMALL CELL CANCER; LYMPH NODE METASTASIS; METASTASIS; MUTATION; NEUTROPENIA; ONCOGENE; PANCREAS CANCER; PROGNOSIS; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN FAMILY; PROTEIN STRUCTURE; PROTEIN TARGETING; RECTUM CANCER; REVIEW; SIGNAL TRANSDUCTION; SQUAMOUS CELL CARCINOMA; SURVIVAL RATE; SURVIVAL TIME; TREATMENT FAILURE; TUMOR GROWTH; UNSPECIFIED SIDE EFFECT; UPREGULATION;

HUMANS; NEOPLASM METASTASIS; ONCOGENE PROTEINS V-ERBB;

EID: 62549119577     PISSN: 15680096     EISSN: None     Source Type: Journal    
DOI: 10.2174/156800909787314048     Document Type: Review

References (221)

1. Olayioye, M. A.; Neve, R. M.; Lane, H. A.; Hynes, N. E. The ErbB signaling network: receptor heterodimerization in development and cancer. EMBO J. 2000, 19, 3159-3167.
2. Yarden, Y.; Sliwkowski, M. X. Untangling the ErbB signalling network. Nat. Rev. Mol. Cell Biol. 2001, 2, 127-137.
3. Normanno, N.; Bianco, C.; De Luca, A.; Maiello, M. R.; Salomon, D. S. Target-based agents against ErbB receptors and their ligands: a novel approach to cancer treatment. Endocr. Relat. Cancer 2003, 10, 1-21.
4. Hynes, N. E.; Lane, H. A. ERBB receptors and cancer: the complexity of targeted inhibitors. Nat. Rev. Cancer 2005, 5, 341-354.
5. rd. Insect cell-expressed p180erbB3 possesses an impaired tyrosine kinase activity. Proc. Natl. Acad. Sci. USA 1994, 91, 8132-8136.
6. Uchida, T.; Wada, K.; Akamatsu, T.; Yonezawa, M.; Noguchi, H.; Mizoguchi, A.; Kasuga, M.; Sakamoto, C. A novel epidermal growth factor-like molecule containing two follistatin modules stimulates tyrosine phosphorylation of erbB-4 in MKN28 gastric cancer cells. Biochem. Biophys. Res. Commun. 1999, 266, 593-602.
7. Harari, D.; Yarden, Y. Molecular mechanisms underlying ErbB2/HER2 action in breast cancer. Oncogene 2000, 19, 6102-6114.
8. Tzahar, E.; Waterman, H.; Chen, X.; Levkowitz, G.; Karunagaran, D.; Lavi, S.; Ratzkin, B. J.; Yarden, Y. A hierarchical network of interreceptor interactions determines signal transduction by Neu differentiation factor/neuregulin and epidermal growth factor. Mol. Cell Biol. 1996, 16, 5276-5287.
9. Graus-Porta, D.; Beerli, R. R.; Daly, J. M.; Hynes, N. E. ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling. EMBO J. 1997, 16, 1647-1655.
10. Riese, D. J., 2nd; Stern, D. F. Specificity within the EGF family/ErbB receptor family signaling network. Bioessays 1998, 20, 41-48.
11. Garrett, T. P.; McKern, N. M.; Lou, M.; Elleman, T. C.; Adams, T. E.; Lovrecz, G. O.; Zhu, H. J.; Walker, F.; Frenkel, M. J.; Hoyne, P. A.; Jorissen, R. N.; Nice, E. C.; Burgess, A. W.; Ward, C. W. Crystal structure of a truncated epidermal growth factor receptor extracellular domain bound to transforming growth factor alpha. Cell 2002, 110, 763-773.
12. Ogiso, H.; Ishitani, R.; Nureki, O.; Fukai, S.; Yamanaka, M.; Kim, J. H.; Saito, K.; Sakamoto, A.; Inoue, M.; Shirouzu, M.; Yokoyama, S. Crystal structure of the complex of human epidermal growth factor and receptor extracellular domains. Cell 2002, 110, 775-87.
13. Garrett, T. P.; McKern, N. M.; Lou, M.; Elleman, T. C.; Adams, T. E.; Lovrecz, G. O.; Kofler, M.; Jorissen, R. N.; Nice, E. C.; Burgess, A. W.; Ward, C. W. The crystal structure of a truncated ErbB2 ectodomain reveals an active conformation, poised to interact with other ErbB receptors. Mol. Cell 2003, 11, 495-505.
14. Schulze, W. X.; Deng, L.; Mann, M. Phosphotyrosine interactome of the ErbB-receptor kinase family. Mol. Syst. Biol. 2005, 1, 2005 0008.
15. Olayioye, M. A.; Graus-Porta, D.; Beerli, R. R.; Rohrer, J.; Gay, B.; Hynes, N. E. ErbB-1 and ErbB-2 acquire distinct signaling properties dependent upon their dimerization partner. Mol. Cell. Biol. 1998, 18, 5042-5051.
16. Olayioye, M. A.; Beuvink, I.; Horsch, K.; Daly, J. M.; Hynes, N. E. ErbB receptor-induced activation of stat transcription factors is mediated by Src tyrosine kinases. J. Biol. Chem. 1999, 274, 17209-17218.
17. Chen, B.; Bronson, R. T.; Klaman, L. D.; Hampton, T. G.; Wang, J. F.; Green, P. J.; Magnuson, T.; Douglas, P. S.; Morgan, J. P.; Neel, B. G. Mice mutant for Egfr and Shp2 have defective cardiac semilunar valvulogenesis. Nat. Genet. 2000, 24, 296-299.
18. Sibilia, M.; Wagner, B.; Hoebertz, A.; Elliott, C.; Marino, S.; Jochum, W.; Wagner, E. F. Mice humanised for the EGF receptor display hypomorphic phenotypes in skin, bone and heart. Development 2003, 130, 4515-4525.
19. Wang, K.; Yamamoto, H.; Chin, J. R.; Werb, Z.; Vu, T. H. Epidermal growth factor receptor-deficient mice have delayed primary endochondral ossification because of defective osteoclast recruitment. J. Biol. Chem. 2004, 279, 53848-53856.
20. Miettinen, P. J.; Berger, J. E.; Meneses, J.; Phung, Y.; Pedersen, R. A.; Werb, Z.; Derynck, R. Epithelial immaturity and multiorgan failure in mice lacking epidermal growth factor receptor. Nature 1995, 376, 337-341.
21. Sibilia, M.; Wagner, E. F. Strain-dependent epithelial defects in mice lacking the EGF receptor. Science 1995, 269, 234-238.
22. Threadgill, D. W.; Dlugosz, A. A.; Hansen, L. A.; Tennenbaum, T.; Lichti, U.; Yee, D.; LaMantia, C.; Mourton, T.; Herrup, K.; Harris, R. C.; Barnard, J. A.; Yuspa, S. H.; Coffey, R. J.; Magnuson, T. Targeted disruption of mouse EGF receptor: effect of genetic background on mutant phenotype. Science 1995, 269, 230-234.
23. Kornblum, H. I.; Hussain, R.; Wiesen, J.; Miettinen, P.; Zurcher, S. D.; Chow, K.; Derynck, R.; Werb, Z. Abnormal astrocyte development and neuronal death in mice lacking the epidermal growth factor receptor. J. Neurosci. Res. 1998, 53, 697-717.
24. Sibilia, M.; Steinbach, J. P.; Stingl, L.; Aguzzi, A.; Wagner, E. F. A strain-independent postnatal neurodegeneration in mice lacking the EGF receptor. EMBO J. 1998, 17, 719-731.
25. Morris, J. K.; Lin, W.; Hauser, C.; Marchuk, Y.; Getman, D.; Lee, K. F. Rescue of the cardiac defect in ErbB2 mutant mice reveals essential roles of ErbB2 in peripheral nervous system development. Neuron 1999, 23, 273-283.
26. Lin, W.; Sanchez, H. B.; Deerinck, T.; Morris, J. K.; Ellisman, M.; Lee, K. F. Aberrant development of motor axons and neuromuscu- lar synapses in erbB2-deficient mice. Proc. Natl. Acad. Sci. USA 2000, 97, 1299-1304.
27. Schmucker, J.; Ader, M.; Brockschnieder, D.; Brodarac, A.; Bartsch, U.; Riethmacher, D. erbB3 is dispensable for oligodendrocyte development in vitro and in vivo. Glia 2003, 44, 67-75.
28. Golding, J. P.; Trainor, P.; Krumlauf, R.; Gassmann, M. Defects in pathfinding by cranial neural crest cells in mice lacking the neuregulin receptor ErbB4. Nat. Cell Biol. 2000, 2, 103-109.
29. Flames, N.; Long, J. E.; Garratt, A. N.; Fischer, T. M.; Gassmann, M.; Birchmeier, C.; Lai, C.; Rubenstein, J. L.; Marin, O. Short- and long-range attraction of cortical GABAergic interneurons by neuregulin-1. Neuron 2004, 44, 251-261.
30. Cohen, S. Isolation of a mouse submaxillary gland protein accelerating incisor eruption and eyelid opening in the new-born animal. J. Biol. Chem. 1962, 237, 1555-1562.
31. Xie, W.; Paterson, A. J.; Chin, E.; Nabell, L. M.; Kudlow, J. E. Targeted expression of a dominant negative epidermal growth factor receptor in the mammary gland of transgenic mice inhibits pu- bertal mammary duct development. Mol. Endocrinol. 1997, 11, 1766-1781.
32. Barnard, J. A.; Beauchamp, R. D.; Russell, W. E.; Dubois, R. N.; Coffey, R. J. Epidermal growth factor-related peptides and their relevance to gastrointestinal pathophysiology. Gastroenterology 1995, 108, 564-580.
33. Schroeder, J. A.; Lee, D. C. Dynamic expression and activation of ERBB receptors in the developing mouse mammary gland. Cell. Growth Differ. 1998, 9, 451-464.
34. Darcy, K. M.; Zangani, D.; Wohlhueter, A. L.; Huang, R. Y.; Vaughan, M. M.; Russell, J. A.; Ip, M. M. Changes in ErbB2 (her- 2/neu), ErbB3, and ErbB4 during growth, differentiation, and apoptosis of normal rat mammary epithelial cells. J. Histochem. Cytochem. 2000, 48, 63-80.
35. Luetteke, N. C.; Qiu, T. H.; Fenton, S. E.; Troyer, K. L.; Riedel, R. F.; Chang, A.; Lee, D. C. Targeted inactivation of the EGF and amphiregulin genes reveals distinct roles for EGF receptor ligands in mouse mammary gland development. Development 1999, 126, 2739-50.
36. Silberberg, G.; Darvasi, A.; Pinkas-Kramarski, R.; Navon, R. The involvement of ErbB4 with schizophrenia: association and expression studies. Am. J. Med. Genet. B. Neuropsychiatr. Genet. 2006, 141, 142-148.
37. Xian, C. J. Roles of epidermal growth factor family in the regulation of postnatal somatic growth. Endocr. Rev. 2007, 28, 284-296.
38. Shimizu, N.; Kondo, I.; Gamou, S.; Behzadian, M. A.; Shimizu, Y. Genetic analysis of hyperproduction of epidermal growth factor receptors in human epidermoid carcinoma A431 cells. Somat. Cell Mol. Genet. 1984, 10, 45-53.
39. Mendelsohn, J.; Baselga, J. The EGF receptor family as targets for cancer therapy. Oncogene 2000, 19, 6550-6565.
40. Guy, C. T.; Webster, M. A.; Schaller, M.; Parsons, T. J.; Cardiff, R. D.; Muller, W. J. Expression of the neu protooncogene in the mammary epithelium of transgenic mice induces metastatic disease. Proc. Natl. Acad. Sci. USA 1992, 89, 10578-10582.
41. Brandt, R.; Eisenbrandt, R.; Leenders, F.; Zschiesche, W.; Binas, B.; Juergensen, C.; Theuring, F. Mammary gland specific hEGF receptor transgene expression induces neoplasia and inhibits differentiation. Oncogene 2000, 19, 2129-2137.
42. Schechter, A. L.; Stern, D. F.; Vaidyanathan, L.; Decker, S. J.; Drebin, J. A.; Greene, M. I.; Weinberg, R. A. The neu oncogene: an erb-B-related gene encoding a 185,000-Mr tumour antigen. Nature 1984, 312, 513-6.
43. Di Fiore, P. P.; Segatto, O.; Taylor, W. G.; Aaronson, S. A.; Pierce, J. H. EGF receptor and erbB-2 tyrosine kinase domains confer cell specificity for mitogenic signaling. Science 1990, 248, 79-83.
44. Greulich, H.; Chen, T. H.; Feng, W.; Janne, P. A.; Alvarez, J. V.; Zappaterra, M.; Bulmer, S. E.; Frank, D. A.; Hahn, W. C.; Sellers, W. R.; Meyerson, M. Oncogenic transformation by inhibitor- sensitive and -resistant EGFR mutants. PLoS Med. 2005, 2, e313.
45. Velu, T. J.; Beguinot, L.; Vass, W. C.; Willingham, M. C.; Merlino, G. T.; Pastan, I.; Lowy, D. R. Epidermal-growth-factor- dependent transformation by a human EGF receptor proto- oncogene. Science 1987, 238, 1408-1410.
46. Amundadottir, L. T.; Nass, S. J.; Berchem, G. J.; Johnson, M. D.; Dickson, R. B. Cooperation of TGF alpha and c-Myc in mouse mammary tumorigenesis: coordinated stimulation of growth and suppression of apoptosis. Oncogene 1996, 13, 757-765.
47. Bell, D. W.; Gore, I.; Okimoto, R. A.; Godin-Heymann, N.; Sor-della, R.; Mulloy, R.; Sharma, S. V.; Brannigan, B. W.; Mohapatra, G.; Settleman, J.; Haber, D. A. Inherited susceptibility to lung cancer may be associated with the T790M drug resistance mutation in EGFR. Nat. Genet. 2005, 37, 1315-1316.
48. Kokai, Y.; Myers, J. N.; Wada, T.; Brown, V. I.; LeVea, C. M.; Davis, J. G.; Dobashi, K.; Greene, M. I. Synergistic interaction of p185c-neu and the EGF receptor leads to transformation of rodent fibroblasts. Cell 1989, 58, 287-292.
49. Alimandi, M.; Romano, A.; Curia, M. C.; Muraro, R.; Fedi, P.; Aaronson, S. A.; Di Fiore, P. P.; Kraus, M. H. Cooperative signaling of ErbB3 and ErbB2 in neoplastic transformation and human mammary carcinomas. Oncogene 1995, 10, 1813-1821.
50. Zhang, K.; Sun, J.; Liu, N.; Wen, D.; Chang, D.; Thomason, A.; Yoshinaga, S. K. Transformation of NIH 3T3 cells by HER3 or HER4 receptors requires the presence of HER1 or HER2. J. Biol. Chem. 1996, 271, 3884-3890.
51. Johnson, B. E.; Janne, P. A. Epidermal growth factor receptor mutations in patients with non-small cell lung cancer. Cancer Res. 2005, 65, 7525-7529.
52. Okamoto, I.; Kenyon, L. C.; Emlet, D. R.; Mori, T.; Sasaki, J.; Hirosako, S.; Ichikawa, Y.; Kishi, H.; Godwin, A. K.; Yoshioka, M.; Suga, M.; Matsumoto, M.; Wong, A. J. Expression of constitu- tively activated EGFRvIII in non-small cell lung cancer. Cancer Sci. 2003, 94, 50-56.
53. Wikstrand, C. J.; Hale, L. P.; Batra, S. K.; Hill, M. L.; Humphrey, P. A.; Kurpad, S. N.; McLendon, R. E.; Moscatello, D.; Pegram, C. N.; Reist, C. J.; Traweek, S. T.; Wong, A. J.; Zalutsky, M. R.; Bigner, D. D. Monoclonal antibodies against EGFRvIII are tumor specific and react with breast and lung carcinomas and malignant gliomas. Cancer Res. 1995, 55, 3140-3148.
54. Rae, J. M.; Scheys, J. O.; Clark, K. M.; Chadwick, R. B.; Kiefer, M. C.; Lippman, M. E. EGFR and EGFRvIII expression in primary breast cancer and cell lines. Breast Cancer Res. Treat. 2004, 87, 87-95.
55. Ge, H.; Gong, X.; Tang, C. K. Evidence of high incidence of EG- FRvIII expression and coexpression with EGFR in human invasive breast cancer by laser capture microdissection and immunohisto- chemical analysis. Int. J. Cancer 2002, 98, 357-361.
56. Gwak, G. Y.; Yoon, J. H.; Shin, C. M.; Ahn, Y. J.; Chung, J. K.; Kim, Y. A.; Kim, T. Y.; Lee, H. S. Detection of response- predicting mutations in the kinase domain of the epidermal growth factor receptor gene in cholangiocarcinomas. J. Cancer Res. Clin. Oncol. 2005, 131, 649-652.
57. Lee, J. W.; Soung, Y. H.; Kim, S. Y.; Nam, H. K.; Park, W. S.; Nam, S. W.; Kim, M. S.; Sun, D. I.; Lee, Y. S.; Jang, J. J.; Lee, J. Y.; Yoo, N. J.; Lee, S. H. Somatic mutations of EGFR gene in squamous cell carcinoma of the head and neck. Clin. Cancer Res. 2005, 11, 2879-2882.
58. Nagahara, H.; Mimori, K.; Ohta, M.; Utsunomiya, T.; Inoue, H.; Barnard, G. F.; Ohira, M.; Hirakawa, K.; Mori, M. Somatic mutations of epidermal growth factor receptor in colorectal carcinoma. Clin. Cancer Res. 2005, 11, 1368-1371.
59. Kwak, E. L.; Kim, S.; Zhang, J.; Cardiff, R. D.; Schmidt, E. V.; Haber, D. A. Mammary tumorigenesis following transgenic expression of a dominant negative CHK2 mutant. Cancer Res. 2006, 66, 1923-1928.
60. Tsao, M. S.; Sakurada, A.; Cutz, J. C.; Zhu, C. Q.; Kamel-Reid, S.; Squire, J.; Lorimer, I.; Zhang, T.; Liu, N.; Daneshmand, M.; Marrano, P.; da Cunha Santos, G.; Lagarde, A.; Richardson, F.; Seymour, L.; Whitehead, M.; Ding, K.; Pater, J.; Shepherd, F. A. Erlotinib in lung cancer - molecular and clinical predictors of outcome. N. Engl. J. Med. 2005, 353, 133-144.
61. Sequist, L. V.; Bell, D. W.; Lynch, T. J.; Haber, D. A. Molecular predictors of response to epidermal growth factor receptor antagonists in non-small-cell lung cancer. J. Clin. Oncol. 2007, 25, 587-595.
62. Amann, J.; Kalyankrishna, S.; Massion, P. P.; Ohm, J. E.; Girard, L.; Shigematsu, H.; Peyton, M.; Juroske, D.; Huang, Y.; Stuart Salmon, J.; Kim, Y. H.; Pollack, J. R.; Yanagisawa, K.; Gazdar, A.; Minna, J. D.; Kurie, J. M.; Carbone, D. P. Aberrant epidermal growth factor receptor signaling and enhanced sensitivity to EGFR inhibitors in lung cancer. Cancer Res. 2005, 65, 226-235.
63. Cappuzzo, F.; Varella-Garcia, M.; Shigematsu, H.; Domenichini, I.; Bartolini, S.; Ceresoli, G. L.; Rossi, E.; Ludovini, V.; Gregorc, V.; Toschi, L.; Franklin, W. A.; Crino, L.; Gazdar, A. F.; Bunn, P. A., Jr.; Hirsch, F. R. Increased HER2 gene copy number is associated with response to gefitinib therapy in epidermal growth factor receptor-positive non-small-cell lung cancer patients. J. Clin. Oncol. 2005, 23, 5007-5018.
64. McLendon, R. E.; Wikstrand, C. J.; Matthews, M. R.; Al-Baradei, R.; Bigner, S. H.; Bigner, D. D. Glioma-associated antigen expression in oligodendroglial neoplasms. Tenascin and epidermal growth factor receptor. J. Histochem. Cytochem. 2000, 48, 1103-1110.
65. Chaffanet, M.; Chauvin, C.; Laine, M.; Berger, F.; Chedin, M.; Rost, N.; Nissou, M. F.; Benabid, A. L. EGF receptor amplification and expression in human brain tumours. Eur. J. Cancer 1992, 28, 11-17.
66. Tsugu, A.; Kijima, H.; Yamazaki, H.; Ohnishi, Y.; Takamiya, Y.; Abe, Y.; Ueyama, Y.; Sato, O.; Tamaoki, N.; Nakamura, M. Localization of aberrant messenger RNA of epidermal growth factor receptor (EGFR) in malignant glioma. Anticancer Res. 1997, 17, 2225-2232.
67. Alvarez, G.; Perry, A.; Tan, B. R.; Wang, H. L. Expression of epidermal growth factor receptor in squamous cell carcinomas of the anal canal is independent of gene amplification. Mod. Pathol. 2006, 19, 942-949.
68. Klijn, J. G.; Berns, P. M.; Schmitz, P. I.; Foekens, J. A. The clinical significance of epidermal growth factor receptor (EGF-R) in human breast cancer: a review on 5232 patients. Endocr. Rev. 1992, 13, 3-17.
69. Libermann, T. A.; Nusbaum, H. R.; Razon, N.; Kris, R.; Lax, I.; Soreq, H.; Whittle, N.; Waterfield, M. D.; Ullrich, A.; Schlessinger, J. Amplification and overexpression of the EGF receptor gene in primary human glioblastomas. J. Cell Sci. Suppl. 1985, 3, 161-172.
70. Semba, K.; Kamata, N.; Toyoshima, K.; Yamamoto, T. A v-erbB- related protooncogene, c-erbB-2, is distinct from the c-erbB- 1/epidermal growth factor-receptor gene and is amplified in a hu-
71. man salivary gland adenocarcinoma. Proc. Natl. Acad. Sci. USA 1985, 82, 6497-6501.
72. Stephens, P.; Hunter, C.; Bignell, G.; Edkins, S.; Davies, H.; Teague, J.; Stevens, C.; O'Meara, S.; Smith, R.; Parker, A.; Barthorpe, A.; Blow, M.; Brackenbury, L.; Butler, A.; Clarke, O.; Cole, J.; Dicks, E.; Dike, A.; Drozd, A.; Edwards, K.; Forbes, S.; Foster, R.; Gray, K.; Greenman, C.; Halliday, K.; Hills, K.; Kosmi- dou, V.; Lugg, R.; Menzies, A.; Perry, J.; Petty, R.; Raine, K.; Ratford, L.; Shepherd, R.; Small, A.; Stephens, Y.; Tofts, C.; Varian, J.; West, S.; Widaa, S.; Yates, A.; Brasseur, F.; Cooper, C. S.; Flanagan, A. M.; Knowles, M.; Leung, S. Y.; Louis, D. N.; Looi-jenga, L. H.; Malkowicz, B.; Pierotti, M. A.; Teh, B.; Chenevix-Trench, G.; Weber, B. L.; Yuen, S. T.; Harris, G.; Goldstraw, P.; Nicholson, A. G.; Futreal, P. A.; Wooster, R.; Stratton, M. R. Lung cancer: intragenic ERBB2 kinase mutations in tumours. Nature 2004, 431, 525-526.
73. Yusa, K.; Sugimoto, Y.; Yamori, T.; Yamamoto, T.; Toyoshima, K.; Tsuruo, T. Low metastatic potential of clone from murine colon adenocarcinoma 26 increased by transfection of activated c-erbB-2 gene. J. Natl. Cancer Inst. 1990, 82, 1633-1636.
74. Slamon, D. J.; Clark, G. M.; Wong, S. G.; Levin, W. J.; Ullrich, A.; McGuire, W. L. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987, 235, 177-182.
75. Sorlie, T.; Perou, C. M.; Tibshirani, R.; Aas, T.; Geisler, S.; John- sen, H.; Hastie, T.; Eisen, M. B.; van de Rijn, M.; Jeffrey, S. S.; Thorsen, T.; Quist, H.; Matese, J. C.; Brown, P. O.; Botstein, D.; Eystein Lonning, P.; Borresen-Dale, A. L. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc. Natl. Acad. Sci. USA 2001, 98, 10869-10874.
76. Kim, M. J.; Ro, J. Y.; Ahn, S. H.; Kim, H. H.; Kim, S. B.; Gong, G. Clinicopathologic significance of the basal-like subtype of breast cancer: a comparison with hormone receptor and Her2/neu- overexpressing phenotypes. Hum. Pathol. 2006, 37, 1217-1226.
77. Leitzel, K.; Teramoto, Y.; Konrad, K.; Chinchilli, V. M.; Volas, G.; Grossberg, H.; Harvey, H.; Demers, L.; Lipton, A. Elevated serum c-erbB-2 antigen levels and decreased response to hormone therapy of breast cancer. J. Clin. Oncol. 1995, 13, 1129-1135.
78. Kraus, M. H.; Issing, W.; Miki, T.; Popescu, N. C.; Aaronson, S. A. Isolation and characterization of ERBB3, a third member of the ERBB/epidermal growth factor receptor family: evidence for over- expression in a subset of human mammary tumors. Proc. Natl. Acad. Sci. USA 1989, 86, 9193-9197.
79. Naidu, R.; Yadav, M.; Nair, S.; Kutty, M. K. Expression of c-erbB3 protein in primary breast carcinomas. Br. J. Cancer 1998, 78, 1385-1390.
80. Yi, E. S.; Harclerode, D.; Gondo, M.; Stephenson, M.; Brown, R. W.; Younes, M.; Cagle, P. T. High c-erbB-3 protein expression is associated with shorter survival in advanced non-small cell lung carcinomas. Mod. Pathol. 1997, 10, 142-148.
81. Shintani, S.; Funayama, T.; Yoshihama, Y.; Alcalde, R. E.; Matsumura, T. Prognostic significance of ERBB3 overexpression in oral squamous cell carcinoma. Cancer Lett. 1995, 95, 79-83.
82. Lemoine, N. R.; Barnes, D. M.; Hollywood, D. P.; Hughes, C. M.; Smith, P.; Dublin, E.; Prigent, S. A.; Gullick, W. J.; Hurst, H. C. Expression of the ERBB3 gene product in breast cancer. Br. J. Cancer 1992, 66, 1116-1121.
83. Rajkumar, T.; Stamp, G. W.; Hughes, C. M.; Gullick, W. J. c-erbB3 protein expression in ovarian cancer. Clin. Mol. Pathol. 1996, 49, M199-M202.
84. Bodey, B.; Bodey, B., Jr.; Groger, A. M.; Luck, J. V.; Siegel, S. E.; Taylor, C. R.; Kaiser, H. E. Clinical and prognostic significance of the expression of the c-erbB-2 and c-erbB-3 oncoproteins in primary and metastatic malignant melanomas and breast carcinomas. Anticancer Res. 1997, 17, 1319-1330.
85. Gilbertson, R. J.; Perry, R. H.; Kelly, P. J.; Pearson, A. D.; Lunec, J. Prognostic significance of HER2 and HER4 coexpression in childhood medulloblastoma. Cancer Res. 1997, 57, 3272-3280.
86. Park, B. H.; Davidson, N. E. PI3 kinase activation and response to Trastuzumab Therapy: what's neu with herceptin resistance? Cancer Cell 2007, 12, 297-299.
87. Moasser, M. M.; Basso, A.; Averbuch, S. D.; Rosen, N. The tyro- sine kinase inhibitor ZD1839 ("Iressa") inhibits HER2-driven signaling and suppresses the growth of HER2-overexpressing tumor cells. Cancer Res. 2001, 61, 7184-7188.
88. Bianco, R.; Shin, I.; Ritter, C. A.; Yakes, F. M.; Basso, A.; Rosen, N.; Tsurutani, J.; Dennis, P. A.; Mills, G. B.; Arteaga, C. L. Loss of PTEN/MMAC1/TEP in EGF receptor-expressing tumor cells counteracts the antitumor action of EGFR tyrosine kinase inhibitors. Oncogene 2003, 22, 2812-2822.
89. Normanno, N.; De Luca, A.; Maiello, M. R.; Campiglio, M.; Na- politano, M.; Mancino, M.; Carotenuto, A.; Viglietto, G.; Menard, S. The MEK/MAPK pathway is involved in the resistance of breast cancer cells to the EGFR tyrosine kinase inhibitor gefitinib. J. Cell Physiol. 2006, 207, 420-427.
90. Normanno, N.; Campiglio, M.; Maiello, M. R.; De Luca, A.; Manc- ino, M.; Gallo, M.; D'Alessio, A.; Menard, S. Breast cancer cells with acquired resistance to the EGFR tyrosine kinase inhibitor ge- fitinib show persistent activation of MAPK signaling. Breast Cancer Res. Treat. 2008, 112, 25-33.
91. Baulida, J.; Kraus, M. H.; Alimandi, M.; Di Fiore, P. P.; Carpenter, G. All ErbB receptors other than the epidermal growth factor receptor are endocytosis impaired. J. Biol. Chem. 1996, 271, 5251-5257.
92. Huang, G.; Chantry, A.; Epstein, R. J. Overexpression of ErbB2 impairs ligand-dependent downregulation of epidermal growth factor receptors via a post-transcriptional mechanism. J. Cell Biochem. 1999, 74, 23-30.
93. Kwong, K. Y.; Hung, M. C. A novel splice variant of HER2 with increased transformation activity. Mol. Carcinog. 1998, 23, 62-68.
94. Christianson, T. A.; Doherty, J. K.; Lin, Y. J.; Ramsey, E. E.; Holmes, R.; Keenan, E. J.; Clinton, G. M. NH2-terminally truncated HER-2/neu protein: relationship with shedding of the extracellular domain and with prognostic factors in breast cancer. Cancer Res. 1998, 58, 5123-5129.
95. Freeman, M. Complexity of EGF receptor signalling revealed in Drosophila. Curr. Opin. Genet. Dev. 1998, 8, 407-411.
96. Jemal, A.; Murray, T.; Ward, E.; Samuels, A.; Tiwari, R. C.; Gha-foor, A.; Feuer, E. J.; Thun, M. J. Cancer statistics, 2005. CA Cancer J. Clin. 2005, 55, 10-30.
97. Chua, D. T.; Nicholls, J. M.; Sham, J. S.; Au, G. K. Prognostic value of epidermal growth factor receptor expression in patients with advanced stage nasopharyngeal carcinoma treated with induction chemotherapy and radiotherapy. Int. J. Radiat. Oncol. Biol. Phys. 2004, 59, 11-20.
98. Jonjic, N.; Kovac, K.; Krasevic, M.; Valkovic, T.; Ernjak, N.; Sasso, F.; Melato, M. Epidermal growth factor-receptor expression correlates with tumor cell proliferation and prognosis in gastric cancer. Anticancer Res. 1997, 17, 3883-3888.
99. Neal, D. E.; Sharples, L.; Smith, K.; Fennelly, J.; Hall, R. R.; Harris, A. L. The epidermal growth factor receptor and the prognosis of bladder cancer. Cancer 1990, 65, 1619-1625.
100. Radinsky, R.; Risin, S.; Fan, D.; Dong, Z.; Bielenberg, D.; Bucana, C. D.; Fidler, I. J. Level and function of epidermal growth factor receptor predict the metastatic potential of human colon carcinoma cells. Clin. Cancer Res. 1995, 1, 19-31.
101. Tobita, K.; Kijima, H.; Dowaki, S.; Kashiwagi, H.; Ohtani, Y.; Oida, Y.; Yamazaki, H.; Nakamura, M.; Ueyama, Y.; Tanaka, M.; Inokuchi, S.; Makuuchi, H. Epidermal growth factor receptor expression in human pancreatic cancer: Significance for liver metastasis. Int. J. Mol. Med. 2003, 11, 305-309.
102. Zhou, X.; Temam, S.; Oh, M.; Pungpravat, N.; Huang, B. L.; Mao, L.; Wong, D. T. Global expression-based classification of lymph node metastasis and extracapsular spread of oral tongue squamous cell carcinoma. Neoplasia 2006, 8, 925-932.
103. Chung, C. H.; Parker, J. S.; Karaca, G.; Wu, J.; Funkhouser, W. K.; Moore, D.; Butterfoss, D.; Xiang, D.; Zanation, A.; Yin, X.; Shockley, W. W.; Weissler, M. C.; Dressler, L. G.; Shores, C. G.; Yar-brough, W. G.; Perou, C. M. Molecular classification of head and neck squamous cell carcinomas using patterns of gene expression. Cancer Cell 2004, 5, 489-500.
104. Aguirre Ghiso, J. A.; Kovalski, K.; Ossowski, L. Tumor dormancy induced by downregulation of urokinase receptor in human carcinoma involves integrin and MAPK signaling. J. Cell. Biol. 1999, 147, 89-104.
105. Lacroix, H.; Iglehart, J. D.; Skinner, M. A.; Kraus, M. H. Overex-pression of erbB-2 or EGF receptor proteins present in early stage mammary carcinoma is detected simultaneously in matched primary tumors and regional metastases. Oncogene 1989, 4, 145-151.
106. Yu, D. H.; Hung, M. C. Expression of activated rat neu oncogene is sufficient to induce experimental metastasis in 3T3 cells. Oncogene 1991, 6, 1991-1996.
107. Tan, M.; Yao, J.; Yu, D. Overexpression of the c-erbB-2 gene enhanced intrinsic metastasis potential in human breast cancer cells without increasing their transformation abilities. Cancer Res. 1997, 57, 1199-1205.
108. Ishida, H.; Sadahiro, S.; Suzuki, T.; Ishikawa, K.; Tajima, T.; Makuuchi, H. c-erbB-2 protein expression and clinicopathologic features in colorectal cancer. Oncol. Rep. 2000, 7, 1229-1233.
109. Ougolkov, A.; Yamashita, K.; Bilim, V.; Takahashi, Y.; Mai, M.; Minamoto, T. Abnormal expression of E-cadherin, beta-catenin, and c-erbB-2 in advanced gastric cancer: its association with liver metastasis. Int. J. Colorectal Dis. 2003, 18, 160-166.
110. Yokoyama, H.; Ikehara, Y.; Kodera, Y.; Ikehara, S.; Yatabe, Y.; Mochizuki, Y.; Koike, M.; Fujiwara, M.; Nakao, A.; Tatematsu, M.; Nakanishi, H. Molecular basis for sensitivity and acquired resistance to gefitinib in HER2-overexpressing human gastric cancer cell lines derived from liver metastasis. Br. J. Cancer 2006, 95, 1504-1513.
111. Chariyalertsak, S.; Sugano, K.; Ohkura, H.; Mori, Y. Comparison of c-erbB-2 oncoprotein expression in tissue and serum of patients with stomach cancer. Tumour Biol. 1994, 15, 294-303.
112. Nakamura, H.; Kawasaki, N.; Taguchi, M.; Kabasawa, K. Association of HER-2 overexpression with prognosis in nonsmall cell lung carcinoma: a metaanalysis. Cancer 2005, 103, 1865-1873.
113. Onn, A.; Correa, A. M.; Gilcrease, M.; Isobe, T.; Massarelli, E.; Bucana, C. D.; O'Reilly, M. S.; Hong, W. K.; Fidler, I. J.; Putnam, J. B.; Herbst, R. S. Synchronous overexpression of epidermal growth factor receptor and HER2-neu protein is a predictor of poor outcome in patients with stage I non-small cell lung cancer. Clin. Cancer Res. 2004, 10, 136-143.
114. Pantel, K.; Izbicki, J. R.; Angstwurm, M.; Braun, S.; Passlick, B.; Karg, O.; Thetter, O.; Riethmuller, G. Immunocytological detection of bone marrow micrometastasis in operable non-small cell lung cancer. Cancer Res. 1993, 53, 1027-1031.
115. Hayes, D. F.; Yamauchi, H.; Broadwater, G.; Cirrincione, C. T.; Rodrigue, S. P.; Berry, D. A.; Younger, J.; Panasci, L. L.; Millard, F.; Duggan, D. B.; Norton, L.; Henderson, I. C. Circulating HER-2/erbB-2/c-neu (HER-2) extracellular domain as a prognostic factor in patients with metastatic breast cancer: Cancer and Leukemia Group B Study 8662. Clin. Cancer Res. 2001, 7, 2703-2711.
116. Gong, Y.; Booser, D. J.; Sneige, N. Comparison of HER-2 status determined by fluorescence in situ hybridization in primary and metastatic breast carcinoma. Cancer 2005, 103, 1763-1769.
117. Gancberg, D.; Di Leo, A.; Cardoso, F.; Rouas, G.; Pedrocchi, M.; Paesmans, M.; Verhest, A.; Bernard-Marty, C.; Piccart, M. J.; Lar- simont, D. Comparison of HER-2 status between primary breast cancer and corresponding distant metastatic sites. Ann. Oncol. 2002, 13, 1036-1043.
118. Lara, P. N., Jr.; Chee, K. G.; Longmate, J.; Ruel, C.; Meyers, F. J.; Gray, C. R.; Edwards, R. G.; Gumerlock, P. H.; Twardowski, P.; Doroshow, J. H.; Gandara, D. R. Trastuzumab plus docetaxel in HER-2/neu-positive prostate carcinoma: final results from the California Cancer Consortium Screening and Phase II Trial. Cancer 2004, 100, 2125-2131.
119. Ross, J. S.; Sheehan, C. E.; Hayner-Buchan, A. M.; Ambros, R. A.; Kallakury, B. V.; Kaufman, R. P., Jr.; Fisher, H. A.; Rifkin, M. D.; Muraca, P. J. Prognostic significance of HER-2/neu gene amplification status by fluorescence in situ hybridization of prostate carcinoma. Cancer 1997, 79, 2162-2170.
120. Morote, J.; de Torres, I.; Caceres, C.; Vallejo, C.; Schwartz, S., Jr.; Reventos, J. Prognostic value of immunohistochemical expression of the c-erbB-2 oncoprotein in metastasic prostate cancer. Int. J. Cancer 1999, 84, 421-425.
121. Chen, N.; Ye, X. C.; Chu, K.; Navone, N. M.; Sage, E. H.; Yu-Lee, L. Y.; Logothetis, C. J.; Lin, S. H. A secreted isoform of ErbB3 promotes osteonectin expression in bone and enhances the inva- siveness of prostate cancer cells. Cancer Res. 2007, 67, 6544-6548.
122. Cheng, C. J.; Ye, X. C.; Vakar-Lopez, F.; Kim, J.; Tu, S. M.; Chen, D. T.; Navone, N. M.; Yu-Lee, L. Y.; Lin, S. H.; Hu, M. C. Bone microenvironment and androgen status modulate subcellular local-
123. ization of ErbB3 in prostate cancer cells. Mol. Cancer Res. 2007, 5, 675-684.
124. Gee, J. M.; Harper, M. E.; Hutcheson, I. R.; Madden, T. A.; Barrow, D.; Knowlden, J. M.; McClelland, R. A.; Jordan, N.; Wakeling, A. E.; Nicholson, R. I. The antiepidermal growth factor receptor agent gefitinib (ZD1839/Iressa) improves antihormone response and prevents development of resistance in breast cancer in vitro. Endocrinology 2003, 144, 5105-5117.
125. Nishio, Y.; Yamada, Y.; Kokubo, H.; Nakamura, K.; Aoki, S.; Taki, T.; Honda, N.; Nakagawa, A.; Saga, S.; Hara, K. Prognostic significance of immunohistochemical expression of the HER-2/neu oncoprotein in bone metastatic prostate cancer. Urology 2006, 68, 110-115.
126. Oxley, J. D.; Winkler, M. H.; Gillatt, D. A.; Peat, D. S. Her-2/neu oncogene amplification in clinically localised prostate cancer. J. Clin. Pathol. 2002, 55, 118-120.
127. Reese, D. M.; Small, E. J.; Magrane, G.; Waldman, F. M.; Chew, K.; Sudilovsky, D. HER2 protein expression and gene amplification in androgen-independent prostate cancer. Am. J. Clin. Pathol. 2001, 116, 234-239.
128. Shi, Y.; Brands, F. H.; Chatterjee, S.; Feng, A. C.; Groshen, S.; Schewe, J.; Lieskovsky, G.; Cote, R. J. Her-2/neu expression in prostate cancer: high level of expression associated with exposure to hormone therapy and androgen independent disease. J. Urol. 2001, 166, 1514-1519.
129. Gravina, G. L.; Festuccia, C.; Angelucci, A.; Poletti, A.; Capuano, D.; Vicentini, C.; Motta, M.; Bologna, M. Long-term presence of androgens and anti-androgens modulate EGF-receptor expression and MAP-kinase phosphorylation in androgen receptor-prostate positive cancer cells. Int. J. Oncol. 2004, 25, 97-104.
130. Signoretti, S.; Montironi, R.; Manola, J.; Altimari, A.; Tam, C.; Bubley, G.; Balk, S.; Thomas, G.; Kaplan, I.; Hlatky, L.; Hahnfeldt, P.; Kantoff, P.; Loda, M. Her-2-neu expression and progression toward androgen independence in human prostate cancer. J. Natl. Cancer Inst. 2000, 92, 1918-1925.
131. Yeh, S.; Lin, H. K.; Kang, H. Y.; Thin, T. H.; Lin, M. F.; Chang, C. From HER2/Neu signal cascade to androgen receptor and its coac- tivators: a novel pathway by induction of androgen target genes through MAP kinase in prostate cancer cells. Proc. Natl. Acad. Sci. USA 1999, 96, 5458-5463.
132. Yarden, R. I.; Wilson, M. A.; Chrysogelos, S. A. Estrogen suppression of EGFR expression in breast cancer cells: a possible mechanism to modulate growth. J. Cell Biochem. Suppl. 2001, 36, 232-246.
133. Wilson, M. A.; Chrysogelos, S. A. Identification and characterization of a negative regulatory element within the epidermal growth factor receptor gene first intron in hormone-dependent breast cancer cells. J. Cell Biochem. 2002, 85, 601-614.
134. Solorzano, C. C.; Baker, C. H.; Tsan, R.; Traxler, P.; Cohen, P.; Buchdunger, E.; Killion, J. J.; Fidler, I. J. Optimization for the blockade of epidermal growth factor receptor signaling for therapy of human pancreatic carcinoma. Clin. Cancer Res. 2001, 7, 2563-2572.
135. Matsuo, M.; Sakurai, H.; Saiki, I. ZD1839, a selective epidermal growth factor receptor tyrosine kinase inhibitor, shows antimetas- tatic activity using a hepatocellular carcinoma model. Mol. Cancer Ther. 2003, 2, 557-561.
136. Kim, S. J.; Uehara, H.; Karashima, T.; Shepherd, D. L.; Killion, J. J.; Fidler, I. J. Blockade of epidermal growth factor receptor signaling in tumor cells and tumor-associated endothelial cells for therapy of androgen-independent human prostate cancer growing in the bone of nude mice. Clin. Cancer Res. 2003, 9, 1200-1210.
137. Polk, D. B. Epidermal growth factor receptor-stimulated intestinal epithelial cell migration requires phospholipase C activity. Gastro-enterology 1998, 114, 493-502.
138. Hynes, N. E.; Stern, D. F. The biology of erbB-2/neu/HER-2 and its role in cancer. Biochim. Biophys. Acta 1994, 1198, 165-184.
139. Verbeek, B. S.; Adriaansen-Slot, S. S.; Vroom, T. M.; Beckers, T.; Rijksen, G. Overexpression of EGFR and c-erbB2 causes enhanced cell migration in human breast cancer cells and NIH3T3 fibro- blasts. FEBS Lett. 1998, 425, 145-150.
140. Spencer, K. S.; Graus-Porta, D.; Leng, J.; Hynes, N. E.; Klemke, R. L. ErbB2 is necessary for induction of carcinoma cell invasion by ErbB family receptor tyrosine kinases. J. Cell Biol. 2000, 148, 385-397.
141. Elenius, K.; Paul, S.; Allison, G.; Sun, J.; Klagsbrun, M. Activation of HER4 by heparin-binding EGF-like growth factor stimulates chemotaxis but not proliferation. EMBO J. 1997, 16, 1268-1278.
142. Huang, S. M.; Li, J.; Harari, P. M. Molecular inhibition of angio-genesis and metastatic potential in human squamous cell carcinomas after epidermal growth factor receptor blockade. Mol. Cancer Ther. 2002, 1, 507-514.
143. Tsai, M. S.; Shamon-Taylor, L. A.; Mehmi, I.; Tang, C. K.; Lupu, R. Blockage of heregulin expression inhibits tumorigenicity and metastasis of breast cancer. Oncogene 2003, 22, 761-768.
144. Yang, C.; Liu, Y.; Lemmon, M. A.; Kazanietz, M. G. Essential role for Rac in heregulin beta1 mitogenic signaling: a mechanism that involves epidermal growth factor receptor and is independent of ErbB4. Mol. Cell Biol. 2006, 26, 831-842.
145. Nakashima, N.; Rose, D. W.; Xiao, S.; Egawa, K.; Martin, S. S.; Haruta, T.; Saltiel, A. R.; Olefsky, J. M. The functional role of CrkII in actin cytoskeleton organization and mitogenesis. J. Biol. Chem. 1999, 274, 3001-3008.
146. Klemke, R. L.; Cai, S.; Giannini, A. L.; Gallagher, P. J.; de Lane-rolle, P.; Cheresh, D. A. Regulation of cell motility by mitogen-activated protein kinase. J. Cell Biol. 1997, 137, 481-492.
147. Salomon, D. S.; Normanno, N.; Ciardiello, F.; Brandt, R.; Shoyab, M.; Todaro, G. J. The role of amphiregulin in breast cancer. Breast Cancer Res. Treat. 1995, 33, 103-114.
148. Groenestege, W. M.; Thebault, S.; van der Wijst, J.; van den Berg, D.; Janssen, R.; Tejpar, S.; van den Heuvel, L. P.; van Cutsem, E.; Hoenderop, J. G.; Knoers, N. V.; Bindels, R. J. Impaired baso-lateral sorting of pro-EGF causes isolated recessive renal hypo-magnesemia. J. Clin. Invest. 2007, 117, 2260-2267.
149. Toyoda, H.; Komurasaki, T.; Uchida, D.; Morimoto, S. Distribution of mRNA for human epiregulin, a differentially expressed member of the epidermal growth factor family. Biochem. J. 1997, 326(Pt 1), 69-75.
150. Falls, D. L. Neuregulins: functions, forms, and signaling strategies. Exp. Cell Res. 2003, 284, 14-30.
151. Jannot, C. B.; Beerli, R. R.; Mason, S.; Gullick, W. J.; Hynes, N. E. Intracellular expression of a single-chain antibody directed to the EGFR leads to growth inhibition of tumor cells. Oncogene 1996, 13, 275-282.
152. Harris, R. C.; Chung, E.; Coffey, R. J. EGF receptor ligands. Exp. Cell Res. 2003, 284, 2-13.
153. Zwick, E.; Hackel, P. O.; Prenzel, N.; Ullrich, A. The EGF receptor as central transducer of heterologous signalling systems. Trends Pharmacol. Sci. 1999, 20, 408-412.
154. Prenzel, N.; Zwick, E.; Daub, H.; Leserer, M.; Abraham, R.; Wal-lasch, C.; Ullrich, A. EGF receptor transactivation by G-protein- coupled receptors requires metalloproteinase cleavage of proHB-EGF. Nature 1999, 402, 884-888.
155. Banerjee, S.; Hussain, M.; Wang, Z.; Saliganan, A.; Che, M.; Bon- fil, D.; Cher, M.; Sarkar, F. H. In vitro and in vivo molecular evidence for better therapeutic efficacy of ABT-627 and taxotere combination in prostate cancer. Cancer Res. 2007, 67, 3818-3826.
156. Pandiella, A.; Bosenberg, M. W.; Huang, E. J.; Besmer, P.; Massa- gue, J. Cleavage of membrane-anchored growth factors involves distinct protease activities regulated through common mechanisms. J. Biol. Chem. 1992, 267, 24028-24033.
157. Arribas, J.; Coodly, L.; Vollmer, P.; Kishimoto, T. K.; Rose-John, S.; Massague, J. Diverse cell surface protein ectodomains are shed by a system sensitive to metalloprotease inhibitors. J. Biol. Chem. 1996, 271, 11376-11382.
158. Dempsey, P. J.; Meise, K. S.; Yoshitake, Y.; Nishikawa, K.; Coffey, R. J. Apical enrichment of human EGF precursor in Madin- Darby canine kidney cells involves preferential basolateral ecto- domain cleavage sensitive to a metalloprotease inhibitor. J. Cell Biol. 1997, 138, 747-758.
159. Santiskulvong, C.; Rozengurt, E. Galardin (GM 6001), a broad-spectrum matrix metalloproteinase inhibitor, blocks bombesin-and LPA-induced EGF receptor transactivation and DNA synthesis in rat-1 cells. Exp. Cell Res. 2003, 290, 437-446.
160. Langlois, S.; Nyalendo, C.; Di Tomasso, G.; Labrecque, L.; Roghi, C.; Murphy, G.; Gingras, D.; Beliveau, R. Membrane-type 1 matrix metalloproteinase stimulates cell migration through epidermal growth factor receptor transactivation. Mol. Cancer Res. 2007, 5, 569-583.
161. Angelucci, A.; Gravina, G. L.; Rucci, N.; Millimaggi, D.; Festuccia, C.; Muzi, P.; Teti, A.; Vicentini, C.; Bologna, M. Suppression of EGF-R signaling reduces the incidence of prostate cancer metastasis in nude mice. Endocr. Relat. Cancer 2006, 13, 197-210.
162. Guerrero, J.; Santibanez, J. F.; Gonzalez, A.; Martinez, J. EGF receptor transactivation by urokinase receptor stimulus through a mechanism involving Src and matrix metalloproteinases. Exp. Cell Res. 2004, 292, 201-208.
163. Monaghan-Benson, E.; McKeown-Longo, P. J. Urokinase-type plasminogen activator receptor regulates a novel pathway of fi- bronectin matrix assembly requiring Src-dependent transactivation of epidermal growth factor receptor. J. Biol. Chem. 2006, 281, 9450-9459.
164. Stewart, J. R.; O'Brian, C. A. Protein kinase C-{alpha} mediates epidermal growth factor receptor transactivation in human prostate cancer cells. Mol. Cancer Ther. 2005, 4, 726-732.
165. Keely, S. J.; Calandrella, S. O.; Barrett, K. E. Carbachol-stimulated transactivation of epidermal growth factor receptor and mitogen- activated protein kinase in T(84) cells is mediated by intracellular ca(2+), PYK-2, and p60(src). J. Biol. Chem. 2000, 275, 12619-12625.
166. DeWitt, A. E.; Dong, J. Y.; Wiley, H. S.; Lauffenburger, D. A. Quantitative analysis of the EGF receptor autocrine system reveals cryptic regulation of cell response by ligand capture. J. Cell Sci. 2001, 114, 2301-2313.
167. Normanno, N.; Bianco, C.; De Luca, A.; Salomon, D. S. The role of EGF-related peptides in tumor growth. Front. Biosci. 2001, 6, D685-D707.
168. Saeki, T.; Stromberg, K.; Qi, C. F.; Gullick, W. J.; Tahara, E.; Normanno, N.; Ciardiello, F.; Kenney, N.; Johnson, G. R.; Salomon, D. S. Differential immunohistochemical detection of am- phiregulin and cripto in human normal colon and colorectal tumors. Cancer Res. 1992, 52, 3467-3473.
169. Normanno, N.; Kim, N.; Wen, D.; Smith, K.; Harris, A. L.; Plowman, G.; Colletta, G.; Ciardiello, F.; Salomon, D. S. Expression of messenger RNA for amphiregulin, heregulin, and cripto-1, three new members of the epidermal growth factor family, in human breast carcinomas. Breast Cancer Res. Treat. 1995, 35, 293-297.
170. Panico, L.; D'Antonio, A.; Salvatore, G.; Mezza, E.; Tortora, G.; De Laurentiis, M.; De Placido, S.; Giordano, T.; Merino, M.; Salomon, D. S.; Mullick, W. J.; Pettinato, G.; Schnitt, S. J.; Bianco, A. R.; Ciardiello, F. Differential immunohistochemical detection of transforming growth factor alpha, amphiregulin and CRIPTO in human normal and malignant breast tissues. Int. J. Cancer 1996, 65, 51-56.
171. Fontanini, G.; De Laurentiis, M.; Vignati, S.; Chine, S.; Lucchi, M.; Silvestri, V.; Mussi, A.; De Placido, S.; Tortora, G.; Bianco, A. R.; Gullick, W.; Angeletti, C. A.; Bevilacqua, G.; Ciardiello, F. Evaluation of epidermal growth factor-related growth factors and receptors and of neoangiogenesis in completely resected stage I- IIIA non-small-cell lung cancer: amphiregulin and microvessel count are independent prognostic indicators of survival. Clin. Cancer Res. 1998, 4, 241-249.
172. D'Antonio, A.; Losito, S.; Pignata, S.; Grassi, M.; Perrone, F.; De Luca, A.; Tambaro, R.; Bianco, C.; Gullick, W. J.; Johnson, G. R.; Iaffaioli, V. R.; Salomon, D. S.; Normanno, N. Transforming growth factor alpha, amphiregulin and cripto-1 are frequently expressed in advanced human ovarian carcinomas. Int. J. Oncol. 2002, 21, 941-948.
173. Amin, D. N.; Hida, K.; Bielenberg, D. R.; Klagsbrun, M. Tumor endothelial cells express epidermal growth factor receptor (EGFR) but not ErbB3 and are responsive to EGF and to EGFR kinase inhibitors. Cancer Res. 2006, 66, 2173-2180.
174. Baker, C. H.; Kedar, D.; McCarty, M. F.; Tsan, R.; Weber, K. L.; Bucana, C. D.; Fidler, I. J. Blockade of epidermal growth factor receptor signaling on tumor cells and tumor-associated endothelial cells for therapy of human carcinomas. Am. J. Pathol. 2002, 161, 929-938.
175. van Cruijsen, H.; Giaccone, G.; Hoekman, K. Epidermal growth factor receptor and angiogenesis: Opportunities for combined anti- cancer strategies. Int. J. Cancer 2005, 117, 883-888.
176. Sini, P.; Wyder, L.; Schnell, C.; O'Reilly, T.; Littlewood, A.; Brandt, R.; Hynes, N. E.; Wood, J. The antitumor and antiangio- genic activity of vascular endothelial growth factor receptor inhibition is potentiated by ErbB1 blockade. Clin. Cancer Res. 2005, 11, 4521-4532.
177. Hirata, A.; Ogawa, S.; Kometani, T.; Kuwano, T.; Naito, S.; Ku- wano, M.; Ono, M. ZD1839 (Iressa) induces antiangiogenic effects through inhibition of epidermal growth factor receptor tyrosine kinase. Cancer Res. 2002, 62, 2554-2560.
178. Baker, C. H.; Pino, M. S.; Fidler, I. J. Phosphorylated epidermal growth factor receptor on tumor-associated endothelial cells in human renal cell carcinoma is a primary target for therapy by tyrosine kinase inhibitors. Neoplasia 2006, 8, 470-476.
179. Weber, K. L.; Doucet, M.; Price, J. E.; Baker, C.; Kim, S. J.; Fidler, I. J. Blockade of epidermal growth factor receptor signaling leads to inhibition of renal cell carcinoma growth in the bone of nude mice. Cancer Res. 2003, 63, 2940-2947.
180. Normanno, N.; De Luca, A.; Aldinucci, D.; Maiello, M. R.; Manc- ino, M.; D'Antonio, A.; De Filippi, R.; Pinto, A. Gefitinib inhibits the ability of human bone marrow stromal cells to induce osteoclast differentiation: implications for the pathogenesis and treatment of bone metastasis. Endocr. Relat. Cancer 2005, 12, 471-482.
181. Baselga, J.; Tripathy, D.; Mendelsohn, J.; Baughman, S.; Benz, C. C.; Dantis, L.; Sklarin, N. T.; Seidman, A. D.; Hudis, C. A.; Moore, J.; Rosen, P. P.; Twaddell, T.; Henderson, I. C.; Norton, L. Phase II study of weekly intravenous recombinant humanized anti- p185HER2 monoclonal antibody in patients with HER2/neu- overexpressing metastatic breast cancer. J. Clin. Oncol. 1996, 14, 737-744.
182. Sordella, R.; Bell, D. W.; Haber, D. A.; Settleman, J. Gefitinib- sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways. Science 2004, 305, 1163-1167.
183. Jiang, J.; Greulich, H.; Janne, P. A.; Sellers, W. R.; Meyerson, M.; Griffin, J. D. Epidermal growth factor-independent transformation of Ba/F3 cells with cancer-derived epidermal growth factor receptor mutants induces gefitinib-sensitive cell cycle progression. Cancer Res. 2005, 65, 8968-8974.
184. Kobayashi, S.; Ji, H.; Yuza, Y.; Meyerson, M.; Wong, K. K.; Tenen, D. G.; Halmos, B. An alternative inhibitor overcomes resistance caused by a mutation of the epidermal growth factor receptor. Cancer Res. 2005, 65, 7096-7101.
185. Bell, D. W.; Lynch, T. J.; Haserlat, S. M.; Harris, P. L.; Okimoto, R. A.; Brannigan, B. W.; Sgroi, D. C.; Muir, B.; Riemenschneider, M. J.; Iacona, R. B.; Krebs, A. D.; Johnson, D. H.; Giaccone, G.; Herbst, R. S.; Manegold, C.; Fukuoka, M.; Kris, M. G.; Baselga, J.; Ochs, J. S.; Haber, D. A. Epidermal growth factor receptor mutations and gene amplification in non-small-cell lung cancer: molecular analysis of the IDEAL/INTACT gefitinib trials. J. Clin. Oncol. 2005, 23, 8081-8092.
186. Frederick, L.; Wang, X. Y.; Eley, G.; James, C. D. Diversity and frequency of epidermal growth factor receptor mutations in human glioblastomas. Cancer Res. 2000, 60, 1383-1387.
187. Rusch, V.; Klimstra, D.; Venkatraman, E.; Pisters, P. W.; Langen- feld, J.; Dmitrovsky, E. Overexpression of the epidermal growth factor receptor and its ligand transforming growth factor alpha is frequent in resectable non-small cell lung cancer but does not predict tumor progression. Clin. Cancer Res. 1997, 3, 515-522.
188. Fukuoka, M.; Yano, S.; Giaccone, G.; Tamura, T.; Nakagawa, K.; Douillard, J. Y.; Nishiwaki, Y.; Vansteenkiste, J.; Kudoh, S.; Ris- chin, D.; Eek, R.; Horai, T.; Noda, K.; Takata, I.; Smit, E.; Aver- buch, S.; Macleod, A.; Feyereislova, A.; Dong, R. P.; Baselga, J. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected]. J. Clin. Oncol. 2003, 21, 2237-2246.
189. Kris, M. G.; Natale, R. B.; Herbst, R. S.; Lynch, T. J., Jr.; Prager, D.; Belani, C. P.; Schiller, J. H.; Kelly, K.; Spiridonidis, H.; San- dler, A.; Albain, K. S.; Cella, D.; Wolf, M. K.; Averbuch, S. D.; Ochs, J. J.; Kay, A. C. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA 2003, 290, 2149-2158.
190. Perez-Soler, R. The role of erlotinib (Tarceva, OSI 774) in the treatment of non-small cell lung cancer. Clin. Cancer Res. 2004, 10, 4238s-4240s.
191. Pegram, M. D.; Slamon, D. J. Combination therapy with trastuzu- mab (Herceptin) and cisplatin for chemoresistant metastatic breast cancer: evidence for receptor-enhanced chemosensitivity. Semin. Oncol. 1999, 26, 89-95.
192. Slamon, D. J.; Leyland-Jones, B.; Shak, S.; Fuchs, H.; Paton, V.; Bajamonde, A.; Fleming, T.; Eiermann, W.; Wolter, J.; Pegram, M.; Baselga, J.; Norton, L. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overex-presses HER2. N. Engl. J. Med. 2001, 344, 783-792.
193. O'Shaughnessy, J. A.; Vukelja, S.; Marsland, T.; Kimmel, G.; Ratnam, S.; Pippen, J. E. Phase II study of trastuzumab plus gem- citabine in chemotherapy-pretreated patients with metastatic breast cancer. Clin. Breast Cancer 2004, 5, 142-147.
194. Gori, S.; Colozza, M.; Mosconi, A. M.; Franceschi, E.; Basurto, C.; Cherubini, R.; Sidoni, A.; Rulli, A.; Bisacci, C.; De Angelis, V.; Crino, L.; Tonato, M. Phase II study of weekly paclitaxel and tras- tuzumab in anthracycline- and taxane-pretreated patients with HER2-overexpressing metastatic breast cancer. Br. J. Cancer 2004, 90, 36-40.
195. Burris, H., 3rd; Yardley, D.; Jones, S.; Houston, G.; Broome, C.; Thompson, D.; Greco, F. A.; White, M.; Hainsworth, J. Phase II trial of trastuzumab followed by weekly paclitaxel/carboplatin as first-line treatment for patients with metastatic breast cancer. J. Clin. Oncol. 2004, 22, 1621-1629.
196. Marty, M.; Cognetti, F.; Maraninchi, D.; Snyder, R.; Mauriac, L.; Tubiana-Hulin, M.; Chan, S.; Grimes, D.; Anton, A.; Lluch, A.; Kennedy, J.; O'Byrne, K.; Conte, P.; Green, M.; Ward, C.; Mayne, K.; Extra, J. M. Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group. J. Clin. Oncol. 2005, 23, 4265-4274.
197. Robert, N.; Leyland-Jones, B.; Asmar, L.; Belt, R.; Ilegbodu, D.; Loesch, D.; Raju, R.; Valentine, E.; Sayre, R.; Cobleigh, M.; Al- bain, K.; McCullough, C.; Fuchs, L.; Slamon, D. Randomized phase III study of trastuzumab, paclitaxel, and carboplatin compared with trastuzumab and paclitaxel in women with HER-2- overexpressing metastatic breast cancer. J. Clin. Oncol. 2006, 24, 2786-2792.
198. Chan, A.; Martin, M.; Untch, M.; Gil, M. G.; Guillem-Porta, V.; Wojtukiewicz, M.; Kellokumpu-Lehtinen, P.; Sommer, H. L.; Georgoulias, V.; Battelli, N.; Pawlicki, M.; Aubert, D.; Bourlard, T.; Gasmi, J.; Villanova, G.; Petruzelka, L. Vinorelbine plus trastu- zumab combination as first-line therapy for HER 2-positive metas- tatic breast cancer patients: an international phase II trial. Br. J. Cancer 2006, 95, 788-793.
199. Mass, R. D.; Press, M. F.; Anderson, S.; Cobleigh, M. A.; Vogel, C. L.; Dybdal, N.; Leiberman, G.; Slamon, D. J. Evaluation of clinical outcomes according to HER2 detection by fluorescence in situ hybridization in women with metastatic breast cancer treated with trastuzumab. Clin. Breast Cancer 2005, 6, 240-246.
200. de Alava, E.; Ocana, A.; Abad, M.; Montero, J. C.; Esparis- Ogando, A.; Rodriguez, C. A.; Otero, A. P.; Hernandez, T.; Cruz, J. J.; Pandiella, A. Neuregulin expression modulates clinical response to trastuzumab in patients with metastatic breast cancer. J. Clin. Oncol. 2007, 25, 2656-2663.
201. Venturini, M.; Bighin, C.; Monfardini, S.; Cappuzzo, F.; Olmeo, N.; Durando, A.; Puglisi, F.; Nicoletto, O.; Lambiase, A.; Del Mas- tro, L. Multicenter phase II study of trastuzumab in combination with epirubicin and docetaxel as first-line treatment for HER2- overexpressing metastatic breast cancer. Breast Cancer Res. Treat. 2006, 95, 45-53.
202. Tan-Chiu, E.; Yothers, G.; Romond, E.; Geyer, C. E., Jr.; Ewer, M.; Keefe, D.; Shannon, R. P.; Swain, S. M.; Brown, A.; Fehren- bacher, L.; Vogel, V. G.; Seay, T. E.; Rastogi, P.; Mamounas, E. P.; Wolmark, N.; Bryant, J. Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast cancer: NSABP B-31. J. Clin. Oncol. 2005, 23, 7811-7819.
203. Burstein, H. J.; Lieberman, G.; Slamon, D. J.; Winer, E. P.; Klein, P. Isolated central nervous system metastases in patients with HER2-overexpressing advanced breast cancer treated with first-line trastuzumab-based therapy. Ann. Oncol. 2005, 16, 1772-1777.
204. Bendell, J. C.; Domchek, S. M.; Burstein, H. J.; Harris, L.; Younger, J.; Kuter, I.; Bunnell, C.; Rue, M.; Gelman, R.; Winer, E. Central nervous system metastases in women who receive trastu- zumab-based therapy for metastatic breast carcinoma. Cancer 2003, 97, 2972-2977.
205. Stemmler, H. J.; Schmitt, M.; Harbeck, N.; Willems, A.; Bernhard, H.; Lassig, D.; Schoenberg, S.; Heinemann, V. Application of in- trathecal trastuzumab (Herceptintrade mark) for treatment of men- ingeal carcinomatosis in HER2-overexpressing metastatic breast cancer. Oncol. Rep. 2006, 15, 1373-1377.
206. Barlesi, F.; Tchouhadjian, C.; Doddoli, C.; Villani, P.; Greillier, L.; Kleisbauer, J. P.; Thomas, P.; Astoul, P. Gefitinib (ZD1839, Iressa) in non-small-cell lung cancer: a review of clinical trials from a daily practice perspective. Fundam. Clin. Pharmacol. 2005, 19, 385-393.
207. von Minckwitz, G.; Jonat, W.; Fasching, P.; du Bois, A.; Kleeberg, U.; Luck, H. J.; Kettner, E.; Hifrich, J.; Eiermann, W.; Torode, J.; Schneeweiss, A. A multicentre phase II study on gefitinib in tax- ane- and anthracycline- pretreated metastatic breast cancer. Breast Cancer Res. Treat. 2005, 89, 165-172.
208. Rothenberg, M. L.; LaFleur, B.; Levy, D. E.; Washington, M. K.; Morgan-Meadows, S. L.; Ramanathan, R. K.; Berlin, J. D.; Benson, A. B., 3rd; Coffey, R. J. Randomized phase II trial of the clinical and biological effects of two dose levels of gefitinib in patients with recurrent colorectal adenocarcinoma. J. Clin. Oncol. 2005, 23, 9265-9274.
209. Kirby, A. M.; A'Hern, R. P.; D'Ambrosio, C.; Tanay, M.; Syrigos, K. N.; Rogers, S. J.; Box, C.; Eccles, S. A.; Nutting, C. M.; Harrington, K. J. Gefitinib (ZD1839, Iressa) as palliative treatment in recurrent or metastatic head and neck cancer. Br. J. Cancer 2006, 94, 631-636.
210. Cohen, E. E.; Rosen, F.; Stadler, W. M.; Recant, W.; Stenson, K.; Huo, D.; Vokes, E. E. Phase II trial of ZD1839 in recurrent or me- tastatic squamous cell carcinoma of the head and neck. J. Clin. Oncol. 2003, 21, 1980-1987.
211. Zampino, M. G.; Magni, E.; Massacesi, C.; Zaniboni, A.; Martignetti, A.; Zorzino, L.; Lorizzo, K.; Santoro, L.; Boselli, S.; de Braud, F. First clinical experience of orally active epidermal growth factor receptor inhibitor combined with simplified FOL- FOX6 as first-line treatment for metastatic colorectal cancer. Cancer 2007, 110, 752-758.
212. Ciardiello, F.; Troiani, T.; Caputo, F.; De Laurentiis, M.; Tortora, G.; Palmieri, G.; De Vita, F.; Diadema, M. R.; Orditura, M.; Colan- tuoni, G.; Gridelli, C.; Catalano, G.; De Placido, S.; Bianco, A. R.
213. Phase II study of gefitinib in combination with docetaxel as first- line therapy in metastatic breast cancer. Br. J. Cancer 2006, 94, 1604-1609.
214. Pallis, A. G.; Christofillakis, C.; Tselepatiotis, E.; Agelaki, S.; Vamvakas, L.; Souglakos, J.; Vardakis, N.; Kalykaki, A.; Kotsakis, A.; Argiraki, A.; Mavroudis, D.; Georgoulias, V. Sequential administration of docetaxel followed by maintenance gefitinib, as salvage treatment in patients with advanced NSCLC: a multicenter phase II trial. Lung Cancer 2007, 55, 101-107.
215. Meyerhardt, J. A.; Zhu, A. X.; Enzinger, P. C.; Ryan, D. P.; Clark, J. W.; Kulke, M. H.; Earle, C. C.; Vincitore, M.; Michelini, A.; Sheehan, S.; Fuchs, C. S. Phase II study of capecitabine, ox- aliplatin, and erlotinib in previously treated patients with metastastic colorectal cancer. J. Clin. Oncol. 2006, 24, 1892-1897.
216. Cunningham, D.; Humblet, Y.; Siena, S.; Khayat, D.; Bleiberg, H.; Santoro, A.; Bets, D.; Mueser, M.; Harstrick, A.; Verslype, C.; Chau, I.; Van Cutsem, E. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N. Engl. J. Med. 2004, 351, 337-345.
217. Reynolds, N. A.; Wagstaff, A. J. Cetuximab: in the treatment of metastatic colorectal cancer. Drugs 2004, 64, 109-18; discussion 119-121.
218. Burtness, B. Cetuximab and cisplatin for chemotherapy-refractory squamous cell cancer of the head and neck. J. Clin. Oncol. 2005, 23, 5440-5442.
219. Burris, H. A., 3rd; Hurwitz, H. I.; Dees, E. C.; Dowlati, A.; Black- well, K. L.; O'Neil, B.; Marcom, P. K.; Ellis, M. J.; Overmoyer, B.; Jones, S. F.; Harris, J. L.; Smith, D. A.; Koch, K. M.; Stead, A.; Mangum, S.; Spector, N. L. Phase I safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in heavily pretreated patients with metastatic carcinomas. J. Clin. Oncol. 2005, 23, 5305-5313.
220. Burstein, H. J.; Storniolo, A. M.; Franco, S.; Forster, J.; Stein, S.; Rubin, S.; Salazar, V. M.; Blackwell, K. L. A phase II study of la- patinib monotherapy in chemotherapy-refractory HER2-positive and HER2-negative advanced or metastatic breast cancer. Ann. Oncol. 2008, 19, 1068-1074.
221. Lin, N. U.; Carey, L. A.; Liu, M. C.; Younger, J.; Come, S. E.; Ewend, M.; Harris, G. J.; Bullitt, E.; Van den Abbeele, A. D.; Li, X.; Gelman, R.; Burstein, H. J.; Kasparian, E.; Kirsch, D. G.; Crawford, A.; Hochberg, F.; Winer, E. P. Phase II trial of lapatinib for brain metastases in patients with human epidermal growth factor receptor 2-positive breast cancer. J. Clin. Oncol. 2008, 26, 1993-1999.